One More Full Marks! Annoroad Passed the National Tumor Somatic Cell Mutation External Quality Assessment with Full Mark!

Recently, the National Center for Clinical Examination of the Ministry of Health released the “Results Report of External Quality Assessment of National Tumor Somatic Mutation High-throughput Sequencing Test in 2018”, and Annoroad Gene Technology passed this type of EQA with full mark once again!



A total of 160 laboratories from 19 provinces (municipalities and autonomous regions) participated in this proficiency test, including 27 in Beijing. A total of 138 laboratories returned the results of the quality assessment, and a total of 6 samples were tested. The pass rate was 87.7% (121/138), and the full score was 55.1% (76/138).

The high-throughput sequencing of tumor somatic mutations reported by Annoroad includes point mutations, short fragment deletions, short fragment insertions, and fusion genes. Annoroad tested all the types of genetic mutations involved above.

Annoroad passed the quality evaluation with full mark, which proved the ability and professionalism of Annoroad in tumor high-throughput gene test with strength. It also proved that Annoroad’s comprehensive strength in sample management, process control and quality supervision has been in the leading level in the industry. In the future, Annoroad will adhere to the philosophy of “improving the quality of life with science and innovation” to standardize the test of each sample with high standards and strict requirements, and help the clinical gene diagnosis and treatment of diseases.


Copyright © Annoroad Gene Technology 京ICP备12029022号-1